Targeted treatment for kidney damage in lupus using nanoparticles
Treatment of lupus nephritis with nanoparticles that selectively target kidney glomeruli
This study is testing a new way to treat lupus nephritis by using tiny particles to deliver medicine directly to the damaged parts of your kidneys, aiming to make treatment safer and more effective for people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of South Florida NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11115578 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for lupus nephritis, a serious kidney condition associated with systemic lupus erythematosus (SLE). The approach involves creating nanoparticles that can deliver medication directly to the damaged areas of the kidneys, specifically targeting the glomeruli. By using a combination of liposomes and chitosan nanoparticles, the researchers aim to ensure that the medication is released in a controlled manner, minimizing side effects and improving treatment efficacy. This innovative method seeks to provide a more effective and safer alternative to current immunosuppressive therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lupus nephritis who are experiencing kidney damage due to their autoimmune condition.
Not a fit: Patients with lupus nephritis who are not responsive to targeted therapies or those with end-stage renal disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with lupus nephritis, reducing the need for harsh immunosuppressive drugs.
How similar studies have performed: Other research has shown promise in using targeted nanoparticle delivery systems for various conditions, indicating potential success for this novel approach.
Where this research is happening
Tampa, United States
- University of South Florida — Tampa, United States (Active)
Researchers
- Principal investigator: Liu, Ruisheng — University of South Florida
- Study coordinator: Liu, Ruisheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.